Tuberous Sclerosis: Clinical Trials

16 trials for Tuberous Sclerosis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

11 completed, 2 active not recruiting, 2 recruiting, 1 terminated. 16 Phase 1, 10 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 116Completed 11, Active not recruiting 2, Recruiting 2, Terminated 1
Phase 210Completed 7, Active not recruiting 2, Recruiting 1

Follow Tuberous Sclerosis: new trials by email Literature Review of Tuberous Sclerosis trials Research Report on Tuberous Sclerosis

Trials (filtered) newest first · largest first

All 16 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Safety, Tolerability, and Pharmacokinetics of SVG103 (Paxalisib) in Focal Cortical Dysplasia Type II (FCD-II), Tuberous Sclerosis Complex (TSC) or Hemimegalencephaly (HME)
SVG103 - Focal Cortical Dysplasia, Tuberous Sclerosis Complex (TSC)
Phase 1 / Phase 2RecruitingSovargen122026-07-142026-08-10
Sapu003 in Advanced mTOR-sensitive Solid Tumors
Sapu003, Exemestane 25 MG - Breast Cancer Metastatic, Renal Cell Carcinoma (RCC)
Phase 1RecruitingSAPU NANO (US) LLC272025-12-152026-01-27
Phase 1, Open-label, Drug-drug Interaction Study to Assess Effect Between Radiprodil and the Co-administered Drugs.
Radiprodil + co-administered drugs - Tuberous Sclerosis Complex (TSC), Focal Cortical Dysplasia
Phase 1CompletedGRIN Therapeutics, Inc.182025-05-202025-11-18
Study to Evaluate the Pharmacokinetics and Safety Effects Following Coadministration of Carbamazepine or Itraconazole With Radiprodil in Healthy Adults
Radiprodil with Carbamazepine, Radiprodil with Itraconazole - Tuberous Sclerosis Complex (TSC), Focal Cortical Dysplasia
Phase 1TerminatedGRIN Therapeutics, Inc.302025-05-082025-11-21
Astroscape: A Study of Radiprodil on Safety, Tolerability, Pharmacokinetics, and Effect on Seizures and Behavioral Symptoms in Patients With TSC or FCD Type II
Radiprodil - Tuberous Sclerosis Complex, Focal Cortical Dysplasia
Phase 1 / Phase 2Active not recruitingGRIN Therapeutics, Inc.302024-07-102026-04-01
Study to Investigate LP352 in Subjects With Developmental and Epileptic Encephalopathies
LP352, Placebo - Developmental and Epileptic Encephalopathy, Dravet Syndrome
Phase 1 / Phase 2CompletedLongboard Pharmaceuticals522022-03-032024-11-08
Feasibility of [11C]Acetate-PET in LAM and TSC
[11C]acetate - Lymphangioleiomyomatosis, Tuberous Sclerosis Complex
Phase 1 / Phase 2Active not recruitingBrigham and Women's Hospital72021-08-302026-01-21
Stopping TSC Onset and Progression 2: Epilepsy Prevention in TSC Infants
TAVT-18 (sirolimus) - Tuberous Sclerosis Complex, Epilepsy
Phase 1 / Phase 2CompletedChildren's Hospital Medical Center, Cincinnati52020-09-082024-05-16
Safety of Simvastatin in LAM and TSC
Simvastatin, Sirolimus Oral Product, Everolimus Oral Product - Lymphangioleiomyomatosis, Tuberous Sclerosis Complex
Phase 1 / Phase 2CompletedUniversity of Pennsylvania102014-03-012020-08-25
Tuberous Sclerosis Complex: Facial Angiofibroma Skin Cream
Rapamune - Facial Angiofibroma
Phase 1CompletedLe Bonheur Children's Hospital112013-10-012016-08-19
Assessment of the Pharmacokinetics of Circadin® in Children With Neurodevelopmental Disorders and Sleep Disturbances
Circadin 2 mg, Circadin 10 mg - Sleep Problems
Phase 1CompletedNeurim Pharmaceuticals Ltd.162013-03-012014-04-04
Everolimus (RAD001) Therapy for Epilepsy in Patients With Tuberous Sclerosis Complex (TSC)
Everolimus - Epilepsy, Tuberous Sclerosis Complex
Phase 1 / Phase 2CompletedChildren's Hospital Medical Center, Cincinnati202010-01-012017-03-13
Topical Rapamycin Therapy to Alleviate Cutaneous Manifestations of Tuberous Sclerosis Complex (TSC) and Neurofibromatosis I (NF1)
Skincerity, Skincerity plus sirolimus/rapamycin, Skinercity plus sirolimus/rapamycin - Tuberous Sclerosis, Neurofibromatoses
Phase 1CompletedThe University of Texas Health Science Center, Houston522009-12-012012-02-27
Long Term Follow Up for RAD001 Therapy of Angiomyolipomata in Patients With Tuberous Sclerosis (TSC) and Sporadic Lymphangioleiomyomatosis (LAM)
everolimus (RAD001) - Tuberous Sclerosis, Angiolipoma
Phase 1 / Phase 2CompletedChildren's Hospital Medical Center, Cincinnati202008-12-012013-09-18
Everolimus (RAD001) Therapy of Giant Cell Astrocytoma in Patients With Tuberous Sclerosis Complex
Everolimus - Tuberous Sclerosis, Subependymal Giant Cell Astrocytoma
Phase 1 / Phase 2CompletedChildren's Hospital Medical Center, Cincinnati282007-01-012014-10-20
RAD001 Therapy of Angiomyolipomata in Patients With TS Complex and Sporadic LAM
RAD001 - Tuberous Sclerosis, Lymphangioleiomyomatosis
Phase 1 / Phase 2CompletedChildren's Hospital Medical Center, Cincinnati362005-08-012013-09-25

Narrower conditions

Focal Cortical Dysplasia (4)  ·  Epilepsy (3)  ·  Hereditary Sensory and Autonomic Neuropathies (3)  ·  Lymphangioleiomyomatosis (3)  ·  Angiofibroma (2)  ·  Angelman Syndrome (1)  ·  Angiolipoma (1)  ·  Astrocytoma (1)  ·  Autism Spectrum Disorder (1)  ·  CDKL5 deficiency disorder (1)  ·  Carcinoma, Hepatocellular (1)  ·  Carcinoma, Renal Cell (1)  ·  Epilepsies, Myoclonic (1)  ·  Hemimegalencephaly (1)

Broader conditions

Congenital Abnormalities (16)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (16)  ·  Genetic Diseases, Inborn (16)  ·  Hamartoma (16)  ·  Heredodegenerative Disorders, Nervous System (16)  ·  Malformations of Cortical Development (16)  ·  Malformations of Cortical Development, Group I (16)  ·  Neoplasms (16)  ·  Neoplasms, Multiple Primary (16)  ·  Neoplastic Syndromes, Hereditary (16)  ·  Nervous System Diseases (16)  ·  Nervous System Malformations (16)  ·  Neurocutaneous Syndromes (16)  ·  Neurodegenerative Diseases (16)  ·  Neoplasms by Histologic Type (8)

Interventions

Everolimus (6)  ·  Sirolimus (4)  ·  radiprodil (3)  ·  Carbamazepine (1)  ·  Injections (1)  ·  Itraconazole (1)  ·  Melatonin (1)  ·  Simvastatin (1)  ·  carbon-11 acetate (1)  ·  exemestane (1)

Sponsors

Children's Hospital Medical Center, Cincinnati (5)  ·  GRIN Therapeutics, Inc. (3)  ·  Brigham and Women's Hospital (1)  ·  Le Bonheur Children's Hospital (1)  ·  Longboard Pharmaceuticals (1)  ·  Neurim Pharmaceuticals Ltd. (1)  ·  SAPU NANO (US) LLC (1)  ·  Sovargen (1)  ·  The University of Texas Health Science Center, Houston (1)  ·  University of Pennsylvania (1)

Countries

United States (10)  ·  Australia (6)  ·  Netherlands (2)  ·  Belgium (1)  ·  Canada (1)  ·  Italy (1)  ·  Poland (1)  ·  Spain (1)  ·  United Kingdom (1)

Top investigators

Carmen P Priolo, MD PhD (1)  ·  Darcy Krueger, M.D. Ph.D (1)  ·  Darcy Krueger, MD, PhD (1)  ·  David N Franz, M.D. (1)  ·  Dennis J Dlugos, MD (1)  ·  Frank McCormack, MD (1)  ·  Hope Northrup, MD (1)  ·  James W Wheless, MD (1)  ·  John Bissler, MD (1)  ·  John J. Bissler, M.D. (1)  ·  Mary Kay Koenig, MD (1)  ·  Maryl Kreider, MD, MSCE (1)  ·  Russell Chin (1)  ·  Vera P Krymskaya, PhD, MBA (1)

Results publications

PMID 21047224, PMID 21482669, PMID 22262746, PMID 22934754, PMID 23325902, PMID 23798472, PMID 26381530, PMID 29023494, PMID 30424962, PMID 39331837

NIH funding

2023 (1)